Strengthening Lebanon’s Health Infrastructure: A Strategic Partnership Between the WHO and EIB Global

Introduction

On March 6, 2025, a landmark partnership was solidified at the European Investment Bank (EIB) Group Forum in Luxembourg, marking a pivotal moment for public health in the Middle East. Dr. Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO), and Thomas Östros, Vice-President of the European Investment Bank (EIB Global), formally signed an agreement to deploy a €10 million grant aimed at fortifying Lebanon’s crumbling healthcare architecture.

This initiative comes at a time of profound uncertainty for the Lebanese Republic, which has been grappling with a protracted economic crisis, political instability, and the subsequent degradation of its public services. By re-establishing critical diagnostic infrastructure and ensuring the continuity of life-saving medications, this collaboration seeks to bridge the gap between emergency humanitarian aid and long-term systemic resilience.

The Core Mandate: Rebuilding Public Health Foundations

The €10 million injection is not merely a financial transaction; it is a surgical intervention into the heart of Lebanon’s health system. The program is anchored by two primary objectives: the restoration of the Central Public Health Laboratory (CPHL) and the establishment of a robust pharmaceutical distribution network for the most vulnerable populations.

The Central Public Health Laboratory (CPHL)

For years, the CPHL has been the silent sentinel of Lebanese public health, responsible for disease surveillance, food safety testing, and the diagnostic capacity required to contain infectious outbreaks. However, due to the severe fiscal crisis that began in 2019, the laboratory suffered from chronic underfunding, technical decay, and a brain drain of qualified personnel.

The grant will facilitate the procurement of modern diagnostic equipment, the refurbishment of laboratory facilities, and the implementation of international biosafety standards. By re-establishing this hub, the WHO and EIB aim to restore the nation’s ability to conduct independent surveillance, which is a prerequisite for preventing future pandemics and managing endemic health threats.

Chronic Disease Management

Beyond infrastructure, the partnership addresses an immediate human tragedy. Over 50,000 individuals suffering from non-communicable diseases (NCDs)—including diabetes, cardiovascular conditions, and various forms of cancer—have faced catastrophic disruptions in their treatment regimens. The collapse of the local currency and the subsequent exit of multinational pharmaceutical suppliers from the Lebanese market have rendered essential medications either unavailable or prohibitively expensive. This initiative will centralize the procurement of these life-saving drugs, ensuring that patients who have been left in a state of medical limbo receive the consistent care required to prevent mortality and morbidity.

Chronology of the Crisis and Intervention

To understand the necessity of this €10 million grant, one must look at the timeline of events that precipitated this intervention.

October 2019: The onset of the Lebanese liquidity crisis begins, triggering hyperinflation and a collapse of the banking sector.
2020–2021: The COVID-19 pandemic strikes, overwhelming the already fragile public health system. The Port of Beirut explosion in August 2020 further cripples the healthcare infrastructure in the capital.
2022–2024: The "brain drain" accelerates as thousands of medical professionals and laboratory technicians emigrate. Essential medicine shortages reach a critical peak, forcing the WHO to rely on ad-hoc emergency shipments.
March 2025: Negotiations between the WHO and EIB Global reach fruition. During the EIB Group Forum, the formal agreement is signed, signaling a transition from reactive emergency response to a structured, institutional rebuilding effort.

Supporting Data: The Magnitude of Need

The data surrounding Lebanon’s health sector paints a sobering picture of why international intervention is not just helpful, but vital.

The Economic Barrier: Prior to the crisis, Lebanon’s healthcare system was heavily reliant on imports. When the currency lost over 95% of its value, the cost of medical imports skyrocketed, effectively excluding the middle and lower classes from accessing private healthcare.
Disease Burden: According to the WHO’s regional office for the Eastern Mediterranean, non-communicable diseases account for roughly 80% of all deaths in Lebanon. The disruption of care for patients with hypertension, diabetes, and cancer has led to a significant increase in preventable complications, such as strokes and diabetic ketoacidosis.
Laboratory Capacity: Before the planned restoration, the CPHL’s operational capacity was estimated to be less than 30% of its pre-2019 efficiency. The lack of reagents and broken testing machinery meant that regional health authorities were often "flying blind" during local outbreaks of communicable diseases.

Official Responses: Aligning Global Priorities

During the signing ceremony, the rhetoric from both organizations highlighted a shared commitment to the "Right to Health" as a fundamental human right, even in the face of geopolitical and economic volatility.

Dr. Tedros Adhanom Ghebreyesus (WHO)

The WHO Director-General emphasized that this partnership is a "testament to the power of multilateralism." He stated:

"A strong health system is the ultimate defense against the unpredictable. By investing in the Central Public Health Laboratory, we are not just buying machines; we are buying time and capability for the Lebanese people. Our focus is to ensure that no patient with a chronic condition is forced to choose between their medicine and their dignity."

Thomas Östros (EIB Global)

Representing the European Investment Bank, Vice-President Östros noted that the bank’s involvement underscores the EIB’s commitment to supporting the European Union’s external action goals in the Middle East.

"The EIB is committed to providing more than just financing; we are providing a bridge to stability. Public health is the bedrock of economic recovery. By supporting the most vulnerable, we help prevent the further erosion of the social fabric in Lebanon, which is essential for long-term regional stability."

Implications: A Model for Future Recovery?

The collaboration between the WHO and EIB Global offers a blueprint for how international financial institutions can engage with countries experiencing "poly-crises."

1. The Shift Toward Institutional Resilience

Historically, international aid to Lebanon has often taken the form of humanitarian relief—food baskets, emergency medicine, and tents. While necessary, these actions do not fix the structural rot. The current grant is significant because it is aimed at institutional capacity. By fixing the laboratory, the partners are creating a sustainable asset that will serve the Lebanese population long after the initial grant funds are exhausted.

2. Economic Stability via Health Security

Public health and economic stability are inextricably linked. A healthy workforce is more productive, and a lower burden of chronic disease reduces the long-term strain on the state’s fiscal budget. By subsidizing the cost of chronic disease medication, the initiative relieves the pressure on the Lebanese Ministry of Public Health, allowing the government to redirect scarce resources toward other failing state services.

3. Geopolitical Implications

Lebanon occupies a strategic position in the Levant. The collapse of its public institutions poses a threat to regional health security, as communicable diseases do not recognize national borders. By stabilizing the public health sector, the international community is effectively creating a "health buffer" that benefits the stability of the entire region.

Looking Forward: Challenges and Sustainability

While the €10 million grant is a significant victory, both the WHO and EIB acknowledge that it is a starting point, not a panacea. The success of this initiative depends heavily on the internal governance of the Lebanese health sector.

The primary challenges moving forward include:

Political Transparency: Ensuring that the procurement process for medical supplies remains transparent and immune to the corruption that has historically plagued public sector contracts in the region.
Human Capital Retention: Investing in physical infrastructure is futile if the skilled scientists and doctors continue to leave the country. Part of the initiative must include incentives to retain the technicians and laboratory managers trained to operate the new equipment.
Long-term Financing: Once the grant is depleted, the Lebanese government must demonstrate the ability to assume responsibility for the ongoing costs of reagents, electricity for the lab, and supply chain management.

Conclusion

The March 2025 agreement in Luxembourg represents a beacon of hope for a nation navigating its most difficult chapter in recent history. By focusing on the intersection of diagnostic excellence and the provision of essential medication, the WHO and EIB Global have moved beyond the cycle of crisis management.

As the project unfolds, it will be watched closely by donors and policymakers worldwide. If this partnership succeeds in restoring the Central Public Health Laboratory and stabilizing the drug supply chain, it will prove that even in the most fractured states, targeted, high-level international support can prevent total system collapse. For the 50,000 patients directly impacted, this is more than a policy shift—it is a lifeline. For the Lebanese people, it is a critical step toward reclaiming their public health sovereignty.